Business · 23/06/2011Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for Patent Extension of Fusilev (Levoleucovorin)
Summary
The Food and Drug Administration has officially confirmed the regulatory review period for the patent extension of Fusilev (Levoleucovorin), a human drug product, in accordance with federal regulations.
Original source language: Federal Register — Health and Human ServicesOpen original release →